Mga Batayang Estadistika
| CIK | 1095435 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Portage Biotech Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| September 5, 2025 |
AlphaTON Capital Corp 481,581 Ordinary Shares underlying Warrants Filed Pursuant to Rule 424(b)(3) Registration No. 333-275229 PROSPECTUS SUPPLEMENT (to Prospectus dated November 7, 2023) AlphaTON Capital Corp 481,581 Ordinary Shares underlying Warrants This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated November 7, 2023 (the “Prospectus”), which forms a part of our Registration Statement on Form F |
|
| September 4, 2025 |
AT THE MARKET OFFERING AGREEMENT Exhibit 1.1 AT THE MARKET OFFERING AGREEMENT July 31, 2025 Chardan Capital Markets, LLC 1 Penn Plaza, Suite 4800 New York, NY 10119 Ladies and Gentlemen: Portage Biotech Inc, a corporation organized under the laws of the British Virgin Islands (the “Company”), confirms its agreement (this “Agreement”) with Chardan Capital Markets LLC and its successors and permitted assigns (the “Manager”) as foll |
|
| September 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2025 Commission File Number: 001-40086 ALPHATON CAPITAL CORP (Translation of registrant's name into English) Clarence Thomas Building, P.O. Box 4649, Road Town, Tortola, British Virgi |
|
| September 3, 2025 |
Exhibit 10.14 ASSET MANAGEMENT AGREEMENT This ASSET MANAGEMENT AGREEMENT (this “Agreement”), effective August [●], 2025 (the “Effective Date”), is entered into by and between AlphaTON Capital Corp (the “Client”), and Alpha Sigma Capital, LLC (the “Asset Manager”). WHEREAS, the Client wishes to appoint the Asset Manager to manage certain assets of the Client; and WHEREAS, the Asset Manager wishes t |
|
| September 3, 2025 |
Amendment 1 to Independent Contractor Agreement FOR OWN YOUR OWN DATA TECHNOLOGIES, LLC Exhibit 10.9 Amendment 1 to Independent Contractor Agreement FOR OWN YOUR OWN DATA TECHNOLOGIES, LLC This Amendment (this "Amendment") is made as of August 19, 2025, by and between AlphaTON Capital Corp, a British Virgin Islands business company listed on the Nasdaq Stock Exchange (the "Company"), and Own Your Data Technologies, LLC ("Consultant"). This Amendment modifies the Independent Contracto |
|
| September 3, 2025 |
Amendment 1 to Independent Contractor Agreement FOR ALPHA Sigma Capital Advisors, LLC Exhibit 10.13 Amendment 1 to Independent Contractor Agreement FOR ALPHA Sigma Capital Advisors, LLC This Amendment (this "Amendment") is made as of August 19, 2025, by and between AlphaTON Capital Corp, a British Virgin Islands business company listed on the Nasdaq Stock Exchange (the "Company"), and Alpha Sigma Capital Advisors, LLC ("Consultant"). This Amendment modifies the Independent Contract |
|
| September 3, 2025 |
AlphaTON Capital Corp Launches TON Digital Asset Treasury Strategy for the Telegram Ecosystem Exhibit 99.1 AlphaTON Capital Corp Launches TON Digital Asset Treasury Strategy for the Telegram Ecosystem ● AlphaTON Capital Unlocks Public Market Access to Toncoin (TON) and Telegram’s Billion-User Ecosystem ● Brittany Kaiser, pioneer in data protection, digital assets, and the public equity markets appointed Chief Executive Officer and Board Member ● Formerly Portage Biotech Inc. (Nasdaq: PRTG) |
|
| September 3, 2025 |
PRE-FUNDED ORDINARY SHARES PURCHASE WARRANT alphaton capital corp Exhibit 10.4 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| September 3, 2025 |
Exhibit 10.15 TREASURY MANAGEMENT AGREEMENT This Treasury Management Agreement (this “Agreement”) is made and entered into as of 29 August 2025 (the “Effective Date”), BETWEEN: AlphaTON Capital Corp (formerly Portage Biotech Inc.), a company organized under the laws of the British Virgin Islands, with its principal office at Clarence Thomas Building, P.O. Box 4649, Road Town, Tortola, British Virg |
|
| September 3, 2025 |
SIDE LETTER AGREEMENT (to that certain Securities Purchase Agreement, dated as of August __, 2025) Exhibit 10.5 SIDE LETTER AGREEMENT (to that certain Securities Purchase Agreement, dated as of August , 2025) This Side Letter Agreement (this “Side Letter”) is entered into as of [●], 2025 (the “Effective Date”) by and between Portage Biotech Inc., a company organized under the laws of the British Virgin Islands (the “Company”), and the undersigned purchaser identified on the signature page heret |
|
| September 3, 2025 |
Exhibit 10.3 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of [●], 2025, is entered into by and among AlphaTON Capital Corp, a company organized under the laws of the British Virgin Islands (the “Company”), and the several investors signatory hereto (individually as an “Investor” and collectively together with their respective permitted assigns, the |
|
| September 3, 2025 |
AlphaTON Capital Corp 481,581 Ordinary Shares underlying Warrants Filed Pursuant to Rule 424(b)(3) Registration No. 333-275229 PROSPECTUS SUPPLEMENT (to Prospectus dated November 7, 2023) AlphaTON Capital Corp 481,581 Ordinary Shares underlying Warrants This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated November 7, 2023 (the “Prospectus”), which forms a part of our Registration Statement on Form F |
|
| September 3, 2025 |
INDEPENDENT CONTRACTOR AGREEMENT Exhibit 10.12 INDEPENDENT CONTRACTOR AGREEMENT This Independent Contractor Agreement (this “Agreement”) is made as of August 19, 2025 (the “Effective Date”), by and between AlphaTON Capital Corp, a British Virgin Islands business company listed on the Nasdaq Stock Exchange (the "Company"), and Alpha Sigma Capital Advisors, LLC ("Consultant”). RECITALS WHEREAS, the Company desires to engage Consult |
|
| September 3, 2025 |
Exhibit 10.6 MASTER LOAN AGREEMENT This Master Loan Agreement (the “Agreement”) is dated as of August 30, 2025 by and between BitGo Prime, LLC (“BitGo,” “BitGo Prime,” or “Lender”), a limited liability company organized and existing under the laws of Delaware, and AlphaTON Capital Corp (“Borrower”), a company organized under the laws of British Virgin Islands (each, a “Party” and together, the “Pa |
|
| September 3, 2025 |
Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of August [●], 2025, between AlphaTON Capital Corp, a company organized under the laws of British Virgin Islands (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHERE |
|
| September 3, 2025 |
INDEPENDENT CONTRACTOR AGREEMENT Exhibit 10.8 INDEPENDENT CONTRACTOR AGREEMENT This Independent Contractor Agreement (this “Agreement”) is made as of August 4, 2025 (the “Effective Date”), by and between Portage Biotech Inc., a British Virgin Islands business company listed on the Nasdaq Stock Exchange (the "Company"), and Own Your Data Technologies, LLC ("Consultant”). RECITALS WHEREAS, the Company desires to engage Consultant’s |
|
| September 3, 2025 |
ALPHA AI A WYOMING CORPORATION (Simple Agreement for Future Equity) Exhibit 10.7 THIS INSTRUMENT AND ANY SECURITIES ISSUABLE PURSUANT HERETO HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR UNDER THE SECURITIES LAWS OF CERTAIN STATES AND FOREIGN JURISDICTIONS. THIS INSTURMENT AND ANY SECURITIES INTO WHICH IT MAY CONVERT MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED EXCEPT AS PERMITTED IN |
|
| September 3, 2025 |
ALPHATON CAPITAL CORP Up to $2,841,450 Ordinary Shares Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-286961 PROSPECTUS SUPPLEMENT (to Prospectus dated May 14, 2025) ALPHATON CAPITAL CORP Up to $2,841,450 Ordinary Shares We have entered into an At The Market Offering Agreement, the Sales Agreement, with Chardan Capital Markets, LLC, or the Sales Agent, relating to our ordinary shares, no par value, offered by this prospectus supplemen |
|
| September 3, 2025 |
INDEPENDENT CONTRACTOR AGREEMENT Exhibit 10.11 INDEPENDENT CONTRACTOR AGREEMENT This Independent Contractor Agreement (this “Agreement”) is made as of August 19, 2025, 2025 (the “Effective Date”), by and between AlphaTON Capital Corp, a British Virgin Islands business company listed on the Nasdaq Stock Exchange (the "Company"), and Red Shark Ventures Inc. ("Consultant”). RECITALS WHEREAS, the Company desires to engage Consultant’ |
|
| September 3, 2025 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of August [•], 2025, between AlphaTON Capital Corp, a company organized under the laws of British Virgin Islands (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHERE |
|
| September 3, 2025 |
INDEPENDENT CONTRACTOR AGREEMENT Exhibit 10.10 INDEPENDENT CONTRACTOR AGREEMENT This Independent Contractor Agreement (this “Agreement”) is made as of August 19, 2025 (the “Effective Date”), by and between AlphaTON Capital Corp, a British Virgin Islands business company listed on the Nasdaq Stock Exchange (the "Company"), and Ralph Matthew McKibbin ("Consultant”). RECITALS WHEREAS, the Company desires to engage Consultant to prov |
|
| September 3, 2025 |
Exhibit 99.2 1 AlphaTON Capital Presentation September 2025 Strategic Relationships 2 2 Cautionary Note Regarding Forward - Looking Statements This presentation contains forward - looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not statements of historical fact are forward - looking statements. Words such |
|
| September 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2025 Commission File Number: 001-40086 AlphaTON Capital Corp (Translation of registrant's name into English) Clarence Thomas Building, P.O. Box 4649, Road Town, Tortola, British Virg |
|
| September 3, 2025 |
Exhibit 3.1 Incorporated on 9 April 1973 in the Province of Ontario, Canada as Kamlo Gold Mines Limited and continued as a BVI Business Company on 5 July 2013 Amended and Restated on 25 July 2017 Amended and Restated on 20 June 2022 Amended and Restated on 20 September 2022 Amended and Restated on 11 August 2025 FH CORPORATE SERVICES LTD TERRITORY OF THE BRITISH VIRGIN ISLANDS BVI BUSINESS COMPANI |
|
| September 3, 2025 |
AT THE MARKET OFFERING AGREEMENT Exhibit 1.1 AT THE MARKET OFFERING AGREEMENT July 31, 2025 Chardan Capital Markets, LLC 1 Penn Plaza, Suite 4800 New York, NY 10119 Ladies and Gentlemen: Portage Biotech Inc, a corporation organized under the laws of the British Virgin Islands (the “Company”), confirms its agreement (this “Agreement”) with Chardan Capital Markets LLC and its successors and permitted assigns (the “Manager”) as foll |
|
| September 3, 2025 |
AMENDMENT NO. 1 TO THE SUBSCRIPTION AGREEMENT Exhibit 10.16 AMENDMENT NO. 1 TO THE SUBSCRIPTION AGREEMENT This Amendment No. 1 to the Subscription Agreement (this “Amendment No. 1”) is made and entered into as of August 19, 2025, by and between Portage Biotech Inc., a company formed under the laws of the British Virgin Islands (the “Company”), and Compedica Holdings Limited, a company formed under the laws of the Isle of Man (“Compedica”). RE |
|
| August 1, 2025 |
AMENDMENT NO. 1 TO THE PORTAGE BIOTECH INC. AMENDED AND RESTATED 2021 EQUITY INCENTIVE PLAN Exhibit 4.3 AMENDMENT NO. 1 TO THE PORTAGE BIOTECH INC. AMENDED AND RESTATED 2021 EQUITY INCENTIVE PLAN The Portage Biotech Inc. Amended and Restated 2021 Equity Incentive Plan (the “Plan”) is hereby amended (this “Amendment”) as set forth below, effective as of January 19, 2022, as provided below. 1. Section 3(a). Section 3(a) of the Plan is hereby amended and restated to read in its entirety as |
|
| August 1, 2025 |
Table 1: Newly Registered Securities Exhibit 107 Calculation of Filing Fee Tables S-8 PORTAGE BIOTECH INC. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Ordinary Shares, no par value per share, reserved for issuance under the Portage Biotech Inc. Amende |
|
| August 1, 2025 |
As filed with the Securities and Exchange Commission on August 1, 2025 As filed with the Securities and Exchange Commission on August 1, 2025 Registration No. |
|
| July 28, 2025 |
Portage Biotech Inc. 481,581 Ordinary Shares underlying Warrants Filed Pursuant to Rule 424(b)(3) Registration No. 333-275229 PROSPECTUS SUPPLEMENT (to Prospectus dated November 7, 2023) Portage Biotech Inc. 481,581 Ordinary Shares underlying Warrants This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated November 7, 2023 (the “Prospectus”), which forms a part of our Registration Statement on Form F- |
|
| July 25, 2025 |
Exhibit 4.13 CONSULTING AGREEMENT This Consulting Agreement (this “Agreement”) is made and entered into as of December 12, 2024 but will be effective as of December 15, 2024 (the “Effective Date”) by and between Portage Development Services Inc. (the “Company”), and Arctos Strategy, LLC, a Delaware Limited Liability Company with an address at 47 Gingerbread Hill, Marblehead MA 01945 (“Consultant”) |
|
| July 25, 2025 |
Portage Biotech Inc. 481,581 Ordinary Shares underlying Warrants Filed Pursuant to Rule 424(b)(3) Registration No. 333-275229 PROSPECTUS SUPPLEMENT (to Prospectus dated November 7, 2023) Portage Biotech Inc. 481,581 Ordinary Shares underlying Warrants This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated November 7, 2023 (the “Prospectus”), which forms a part of our Registration Statement on Form F- |
|
| July 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1 |
|
| July 25, 2025 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM EXHIBIT 15.2 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in the Registration Statements on Form S-8 (File No. 333-275842) and Form F-3 (File No. 333-286961) of our report dated August 14, 2024, with respect to the consolidated financial statements of Portage Biotech Inc. included in this Annual Report on Form 20-F for the year ended March 3 |
|
| July 25, 2025 |
EXHIBIT 13.2 CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Andrea Park, Chief Financial Officer of Portage Biotech Inc. (the “Company”), hereby certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge: (i) |
|
| July 25, 2025 |
PORTAGE BIOTECH INC. 2021 EQUITY INCENTIVE PLAN Share Option Agreement Exhibit 4.21 PORTAGE BIOTECH INC. 2021 EQUITY INCENTIVE PLAN Share Option Agreement This Share Option Agreement (this “Agreement”), dated as of the Grant Date, is between Portage Biotech Inc., a corporation formed under the laws of the Territory of the British Virgin Islands (the “Company”), and Adam Melero (the “Optionee”). The Company hereby grants to the Optionee the following option (the “Opti |
|
| July 25, 2025 |
EXHIBIT 13.1 CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Alexander Pickett, Director and Chief Executive Officer of Portage Biotech Inc. (the “Company”), hereby certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of |
|
| July 25, 2025 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM EXHIBIT 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in the Registration Statements on Form S-8 (File No. 333-275842) and Form F-3 (File No. 333-286961) of our report dated July 25, 2025, with respect to the consolidated financial statements of Portage Biotech Inc. included in this Annual Report on Form 20-F for the year ended March 31, |
|
| July 25, 2025 |
CERTIFICATIONS PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 EXHIBIT 12.2 CERTIFICATIONS PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Andrea Park, Chief Financial Officer of Portage Biotech Inc., certify that: 1. I have reviewed this Annual Report on Form 20-F of Portage Biotech Inc. for the fiscal year ended March 31, 2025. 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a mate |
|
| July 25, 2025 |
Portage Biotech Reports Results for Fiscal Year Ended March 31, 2025 EXHIBIT 99.1 Portage Biotech Reports Results for Fiscal Year Ended March 31, 2025 DOVER, Del., July 25, 2025 (GLOBE NEWSWIRE) - Portage Biotech Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology company formed under the laws of the British Virgin Islands, with a portfolio of novel multi-targeted therapies for use as monotherapy and in combination, today reported its |
|
| July 25, 2025 |
Exhibit 4.12 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this “Agreement”) is entered into as of the Effective Date by and between Portage Development Services, Inc., a Delaware Corporation (“Portage”) and Andrea Park (“Employee”). Portage and Employee are sometimes individually referred to herein as a “Party” and collectively as the “Parties”. ARTICLE I EMPLOYMENT DUTIES AND RESPONSIBILITIES; |
|
| July 25, 2025 |
CERTIFICATIONS PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 EXHIBIT 12.1 CERTIFICATIONS PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Alexander Pickett, Director and Chief Executive Officer of Portage Biotech Inc., certify that: 1. I have reviewed this Annual Report on Form 20-F of Portage Biotech Inc. for the fiscal year ended March 31, 2025. 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or o |
|
| July 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2025 Commission File Number: 001-40086 PORTAGE BIOTECH INC. (Translation of registrant's name into English) Clarence Thomas Building, P.O. Box 4649, Road Town, Tortola, British Virgin Isla |
|
| June 27, 2025 |
AT THE MARKET OFFERING AGREEMENT June 27, 2025 Exhibit 1.1 AT THE MARKET OFFERING AGREEMENT June 27, 2025 Rodman & Renshaw LLC 600 Lexington Avenue, 32nd Floor New York, NY 10022 Ladies and Gentlemen: Portage Biotech Inc, a corporation organized under the laws of the British Virgin Islands (the “Company”), confirms its agreement (this “Agreement”) with Rodman & Renshaw LLC and its successors and permitted assigns (the “Manager”) as follows: 1. |
|
| June 27, 2025 |
Portage Biotech Inc. 481,581 Ordinary Shares underlying Warrants Filed Pursuant to Rule 424(b)(3) Registration No. 333-275229 PROSPECTUS SUPPLEMENT (to Prospectus dated November 7, 2023) Portage Biotech Inc. 481,581 Ordinary Shares underlying Warrants This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated November 7, 2023 (the “Prospectus”), which forms a part of our Registration Statement on Form F- |
|
| June 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2025 Commission File Number: 001-40086 PORTAGE BIOTECH INC. (Translation of registrant's name into English) Clarence Thomas Building, P.O. Box 4649, Road Town, Tortola, British Virgin Isla |
|
| June 27, 2025 |
PORTAGE BIOTECH INC. Up to $3,377,250 Ordinary Shares Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-286961 PROSPECTUS SUPPLEMENT (to Prospectus dated May 14, 2025) PORTAGE BIOTECH INC. Up to $3,377,250 Ordinary Shares We have entered into an At The Market Offering Agreement, or the Sales Agreement, with Rodman & Renshaw LLC, or the Sales Agent, relating to our ordinary shares, no par value, offered by this prospectus supplement and |
|
| June 25, 2025 |
Portage Biotech Regains Full Compliance with Nasdaq Continued Listing Requirements EXHIBIT 99.1 Portage Biotech Regains Full Compliance with Nasdaq Continued Listing Requirements DOVER, Del., June 25, 2025 (GLOBE NEWSWIRE) - Portage Biotech Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology company formed under the laws of the British Virgin Islands (“Portage”), announced today that on June 24, 2025, the Company received formal notice from The Nas |
|
| June 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2025 Commission File Number: 001-40086 PORTAGE BIOTECH INC. (Translation of registrant's name into English) Clarence Thomas Building, P.O. Box 4649, Road Town, Tortola, British Virgin Isla |
|
| June 25, 2025 |
Portage Biotech Inc. 481,581 Ordinary Shares underlying Warrants Filed Pursuant to Rule 424(b)(3) Registration No. 333-275229 PROSPECTUS SUPPLEMENT (to Prospectus dated November 7, 2023) Portage Biotech Inc. 481,581 Ordinary Shares underlying Warrants This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated November 7, 2023 (the “Prospectus”), which forms a part of our Registration Statement on Form F- |
|
| June 9, 2025 |
PORTAGE BIOTECH INC. SUBSCRIPTION AGREEMENT Exhibit 10.1 PORTAGE BIOTECH INC. SUBSCRIPTION AGREEMENT As of June 5, 2025 Portage Biotech, Inc. 1111B S Governors Ave #25907 Dover, DE 19904 Ladies and Gentlemen: The undersigned subscriber, Compedica Holdings Limited, with an address at Viking House, Nelson Street, Douglas, Isle of Man IM1 2AH (email for notices: [email protected]) (the “Subscriber”) desires to purchase 625,000 ordinary share |
|
| June 9, 2025 |
Portage Biotech Inc. 481,581 Ordinary Shares underlying Warrants Filed Pursuant to Rule 424(b)(3) Registration No. 333-275229 PROSPECTUS SUPPLEMENT (to Prospectus dated November 7, 2023) Portage Biotech Inc. 481,581 Ordinary Shares underlying Warrants This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated November 7, 2023 (the “Prospectus”), which forms a part of our Registration Statement on Form F- |
|
| June 9, 2025 |
Portage Biotech and Compedica Stock-for-Stock Exchange EXHIBIT 99.1 Portage Biotech and Compedica Stock-for-Stock Exchange DOVER, Del., June 09, 2025 (GLOBE NEWSWIRE) - Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company formed under the laws of the British Virgin Islands (“Portage”) announce that on June 5, 2025 Portage and Compedica Holdings Limited, a company formed under the laws of the Isle of Man (“Compedica”) entered a |
|
| June 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2025 Commission File Number: 001-40086 PORTAGE BIOTECH INC. (Translation of registrant's name into English) Clarence Thomas Building, P.O. Box 4649, Road Town, Tortola, British Virgin Isla |
|
| May 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission File Number: 001-40086 PORTAGE BIOTECH INC. (Translation of registrant's name into English) Clarence Thomas Building, P.O. Box 4649, Road Town, Tortola, British Virgin Islan |
|
| May 29, 2025 |
Exhibit 16 May 29, 2025 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by Portage Biotech, Inc. within its Form 6-K dated May 29, 2025. We agree with the statements concerning our Firm in such Form 6-K; we are not in a position to agree or disagree with other statements of Portage Biotech, Inc. contained therein. Very trul |
|
| May 29, 2025 |
Portage Biotech Inc. 481,581 Ordinary Shares underlying Warrants Filed Pursuant to Rule 424(b)(3) Registration No. 333-275229 PROSPECTUS SUPPLEMENT (to Prospectus dated November 7, 2023) Portage Biotech Inc. 481,581 Ordinary Shares underlying Warrants This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated November 7, 2023 (the “Prospectus”), which forms a part of our Registration Statement on Form F- |
|
| May 21, 2025 |
$40,000,000 PORTAGE BIOTECH INC. Ordinary Shares Filed Pursuant to rule 424(b)(2) Registration Statement No. 333-286961 PROSPECTUS $40,000,000 PORTAGE BIOTECH INC. Ordinary Shares Warrants Units This prospectus relates to ordinary shares, warrants and units that we may sell from time to time in one or more offerings up to a total public offering price of $40,000,000 on terms to be determined at the time of sale. This prospectus only provides a g |
|
| May 12, 2025 |
As filed with the Securities and Exchange Commission on May 12, 2025 As filed with the Securities and Exchange Commission on May 12, 2025 Registration No. |
|
| May 12, 2025 |
Exhibit 107 Calculation of Filing Fee Table Form F-3 (Form Type) Portage Biotech Inc. |
|
| May 12, 2025 |
Portage Biotech Inc. Clarence Thomas Building, P.O. Box 4649 Road Town, Tortola, British Virgin Islands, VG1110 Tel: (302) 219-5556 May 12, 2025 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street N.E. Washington, D.C. 20549 Attention: Tim Buchmiller, Esq. Re: Portage Biotech Inc. Registration Statement on Form F-3, File No. 333-286961 REQUEST FOR ACCELERATION |
|
| May 12, 2025 |
Attorneys at Law | 711 Third Ave., New York, NY 10017-4014 Attorneys at Law | 711 Third Ave., New York, NY 10017-4014 T (212) 907-7300 | F (212) 754-0330 | www.golenbock.com Direct Dial No.: (212) 907-7349 Direct Fax No.: (212) 754-0330 Email Address: AHudders @GOLENBOCK.COM May 12, 2025 United States Securities and Exchange Commission Division of Corporation Finance – Office of Life Sciences Washington, DC 20549 Attention: Mr. Tim Buchmiller Re: Portage |
|
| May 5, 2025 |
As filed with the Securities and Exchange Commission on May 5, 2025 As filed with the Securities and Exchange Commission on May 5, 2025 Registration No. |
|
| May 5, 2025 |
Exhibit 107 Calculation of Filing Fee Table Form F-3 (Form Type) Portage Biotech Inc. |
|
| April 28, 2025 |
EXHIBIT 99.1 Portage Biotech Reports Confirmatory Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7 DOVER, Del., April 28, 2025 (GLOBE NEWSWIRE) - Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company today reports confirmatory preclinical efficacy data for PORT-7 (TT-4), a selective adenosine A2B receptor inhibitor. Dr. Luciano Mutti of the Depa |
|
| April 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025 Commission File Number: 001-40086 PORTAGE BIOTECH INC. (Translation of registrant's name into English) Clarence Thomas Building, P.O. Box 4649, Road Town, Tortola, British Virgin Isl |
|
| April 28, 2025 |
Portage Biotech Inc. 481,581 Ordinary Shares underlying Warrants Filed Pursuant to Rule 424(b)(3) Registration No. 333-275229 PROSPECTUS SUPPLEMENT (to Prospectus dated November 7, 2023) Portage Biotech Inc. 481,581 Ordinary Shares underlying Warrants This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated November 7, 2023 (the “Prospectus”), which forms a part of our Registration Statement on Form F- |
|
| March 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025 Commission File Number: 001-40086 PORTAGE BIOTECH INC. (Translation of registrant's name into English) Clarence Thomas Building, P.O. Box 4649, Road Town, Tortola, British Virgin Isl |
|
| March 27, 2025 |
Portage Biotech Inc. 481,581 Ordinary Shares underlying Warrants Filed Pursuant to Rule 424(b)(3) Registration No. 333-275229 PROSPECTUS SUPPLEMENT (to Prospectus dated November 7, 2023) Portage Biotech Inc. 481,581 Ordinary Shares underlying Warrants This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated November 7, 2023 (the “Prospectus”), which forms a part of our Registration Statement on Form F- |
|
| March 27, 2025 |
EXHIBIT 99.1 Portage Biotech Reports Promising Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7 Encouraging efficacy data in a murine mesothelioma model with a selective A2B adenosine receptor antagonist given as a single agent or in combination with anti-PD-1 antibody DOVER, Del., March 27, 2025 (GLOBE NEWSWIRE) - Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage |
|
| March 13, 2025 |
Portage Biotech Inc. 481,581 Ordinary Shares underlying Warrants Filed Pursuant to Rule 424(b)(3) Registration No. 333-275229 PROSPECTUS SUPPLEMENT (to Prospectus dated November 7, 2023) Portage Biotech Inc. 481,581 Ordinary Shares underlying Warrants This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated November 7, 2023 (the “Prospectus”), which forms a part of our Registration Statement on Form F- |
|
| March 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025 Commission File Number: 001-40086 PORTAGE BIOTECH INC. (Translation of registrant's name into English) Clarence Thomas Building, P.O. Box 4649, Road Town, Tortola, British Virgin Isl |
|
| March 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025 Commission File Number: 001-40086 PORTAGE BIOTECH INC. (Translation of registrant's name into English) Clarence Thomas Building, P.O. Box 4649, Road Town, Tortola, British Virgin Isl |
|
| March 12, 2025 |
Portage Biotech Inc. 481,581 Ordinary Shares underlying Warrants Filed Pursuant to Rule 424(b)(3) Registration No. 333-275229 PROSPECTUS SUPPLEMENT (to Prospectus dated November 7, 2023) Portage Biotech Inc. 481,581 Ordinary Shares underlying Warrants This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated November 7, 2023 (the “Prospectus”), which forms a part of our Registration Statement on Form F- |
|
| March 12, 2025 |
EXHIBIT 99.1 Portage Biotech Resumes Enrollment in Final Cohort of Dose Escalation for Port-6 in ADPORT-601 Trial Encouraging Safety Profile Supports Progression Toward First Dual-Administration of Selective A2A and A2B Antagonists in Patients DOVER, Del., March 12, 2025 (GLOBE NEWSWIRE) - Portage Biotech Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology company wi |
|
| February 12, 2025 |
Portage Biotech Inc. 481,581 Ordinary Shares underlying Warrants Filed Pursuant to Rule 424(b)(3) Registration No. 333-275229 PROSPECTUS SUPPLEMENT (to Prospectus dated November 7, 2023) Portage Biotech Inc. 481,581 Ordinary Shares underlying Warrants This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated November 7, 2023 (the “Prospectus”), which forms a part of our Registration Statement on Form F- |
|
| February 12, 2025 |
EXHIBIT 99.1 Portage Biotech Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements DOVER, Del., Feb. 12, 2025 (GLOBE NEWSWIRE) - Portage Biotech, Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of innovative therapeutics, today announced that on February 11, 2025, it received notification from |
|
| February 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2025 Commission File Number: 001-40086 PORTAGE BIOTECH INC. (Translation of registrant's name into English) Clarence Thomas Building, P.O. Box 4649, Road Town, Tortola, British Virgin |
|
| January 30, 2025 |
PORTAGE BIOTECH, INC. SUBSCRIPTION AGREEMENT Exhibit 4.1 PORTAGE BIOTECH, INC. SUBSCRIPTION AGREEMENT January 23, 2025 Portage Biotech, Inc. 1111B S Governors Ave #25907 Dover, DE 19904 Ladies and Gentlemen: The undersigned subscriber, [Name of Investor] (the “Subscriber”) desires to purchase [Number of Shares] ordinary shares (the “Common Stock”), of Portage Biotech, Inc., a company formed under the laws of the British Virgin Islands (the “ |
|
| January 30, 2025 |
Portage Biotech Inc. 481,581 Ordinary Shares underlying Warrants Filed Pursuant to Rule 424(b)(3) Registration No. 333-275229 PROSPECTUS SUPPLEMENT (to Prospectus dated November 7, 2023) Portage Biotech Inc. 481,581 Ordinary Shares underlying Warrants This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated November 7, 2023 (the “Prospectus”), which forms a part of our Registration Statement on Form F- |
|
| January 30, 2025 |
Portage Biotech Announces Completion of $2.15 Million Private Financing EXHIBIT 99.1 Portage Biotech Announces Completion of $2.15 Million Private Financing DOVER, Del., Jan. 30, 2025 (GLOBE NEWSWIRE) - Portage Biotech, Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of innovative therapeutics, today announced that it has completed a private placement of $2.15 million from two Portage directors. The 524,390 o |
|
| January 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2025 Commission File Number: 001-40086 PORTAGE BIOTECH INC. (Translation of registrant's name into English) Clarence Thomas Building, P.O. Box 4649, Road Town, Tortola, British Virgin I |
|
| January 30, 2025 |
PORTAGE BIOTECH INC. REGISTRATION RIGHTS AGREEMENT Exhibit 4.2 PORTAGE BIOTECH INC. REGISTRATION RIGHTS AGREEMENT This REGISTRATION (this “Agreement”) is made and entered into as of January 23, 2025, by and among PORTAGE BIOTECH INC., a company formed under the laws of The British Virgin Islands (“Company”), the persons listed on Schedule A hereto (individually a “Holder” and collectively as the “Holders”). RECITALS WHEREAS, in connection with the |
|
| January 6, 2025 |
Portage Biotech Inc. 481,581 Ordinary Shares underlying Warrants Filed Pursuant to Rule 424(b)(3) Registration No. 333-275229 PROSPECTUS SUPPLEMENT (to Prospectus dated November 7, 2023) Portage Biotech Inc. 481,581 Ordinary Shares underlying Warrants This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated November 7, 2023 (the “Prospectus”), which forms a part of our Registration Statement on Form F- |
|
| January 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2025 Commission File Number: 001-40086 Portage Biotech Inc. (Translation of registrant’s name into English) Clarence Thomas Building, P.O. Box 4649, Road Town, Tortola, British Virgin |
|
| January 6, 2025 |
EXHIBIT 99.1 Portage Biotech Announce Re-Launch of Adenosine Subsidiary as Independently Managed Company; Appointment of Peter Molloy to Lead New Company WESTPORT, Conn., Jan. 06, 2025 (GLOBE NEWSWIRE) - Portage Biotech, Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of innovative therapeutics, today announced the re-launch of its wholly |
|
| December 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2024 Commission File Number: 001-40086 PORTAGE BIOTECH INC. (Translation of registrant's name into English) Clarence Thomas Building, P.O. Box 4649, Road Town, Tortola, British Virgin |
|
| December 17, 2024 |
Portage Biotech Inc. 481,581 Ordinary Shares underlying Warrants Filed Pursuant to Rule 424(b)(3) Registration No. 333-275229 PROSPECTUS SUPPLEMENT (to Prospectus dated November 7, 2023) Portage Biotech Inc. 481,581 Ordinary Shares underlying Warrants This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated November 7, 2023 (the “Prospectus”), which forms a part of our Registration Statement on Form F- |
|
| December 17, 2024 |
EX-99.1 2 exh991.htm PRESS RELEASE EXHIBIT 99.1 Portage Biotech Announces Letter of Intent with Immunova for an Option to Acquire iOx Therapeutics, Ltd WESTPORT, Conn., Dec. 17, 2024 (GLOBE NEWSWIRE) - Portage Biotech, Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of novel multi-targeted therapies for use as monotherapy and in combinati |
|
| December 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2024 Commission File Number: 001-40086 Portage Biotech Inc. (Translation of registrant’s name into English) Clarence Thomas Building, P.O. Box 4649, Road Town, Tortola, British Virgin |
|
| December 13, 2024 |
Portage Biotech Inc. 481,581 Ordinary Shares underlying Warrants Filed Pursuant to Rule 424(b)(3) Registration No. 333-275229 PROSPECTUS SUPPLEMENT (to Prospectus dated November 7, 2023) Portage Biotech Inc. 481,581 Ordinary Shares underlying Warrants This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated November 7, 2023 (the “Prospectus”), which forms a part of our Registration Statement on Form F- |
|
| December 12, 2024 |
Portage Biotech Inc. 481,581 Ordinary Shares underlying Warrants Filed Pursuant to Rule 424(b)(3) Registration No. 333-275229 PROSPECTUS SUPPLEMENT (to Prospectus dated November 7, 2023) Portage Biotech Inc. 481,581 Ordinary Shares underlying Warrants This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated November 7, 2023 (the “Prospectus”), which forms a part of our Registration Statement on Form F- |
|
| December 12, 2024 |
Portage Biotech Announces Receipt of Nasdaq Noncompliance Letter EXHIBIT 99.1 Portage Biotech Announces Receipt of Nasdaq Noncompliance Letter No impact at this time on the listing of the Company’s Ordinary Shares on Nasdaq Company intends to submit to Nasdaq a compliance plan WESTPORT, Conn., Dec. 12, 2024 (GLOBE NEWSWIRE) - Portage Biotech Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of novel mult |
|
| December 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2024 Commission File Number: 001-40086 Portage Biotech Inc. (Translation of registrant's name into English) British Virgin Islands (Jurisdiction of incorporation or organization) Clare |
|
| December 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2024 Commission File Number: 001-40086 Portage Biotech Inc. (Translation of registrant’s name into English) Clarence Thomas Building, P.O. Box 4649, Road Town, Tortola, British Virgin |
|
| December 5, 2024 |
Portage Biotech Inc. 481,581 Ordinary Shares underlying Warrants Filed Pursuant to Rule 424(b)(3) Registration No. 333-275229 PROSPECTUS SUPPLEMENT (to Prospectus dated November 7, 2023) Portage Biotech Inc. 481,581 Ordinary Shares underlying Warrants This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated November 7, 2023 (the “Prospectus”), which forms a part of our Registration Statement on Form F- |
|
| November 26, 2024 |
Portage Biotech Inc. 481,581 Ordinary Shares underlying Warrants Filed Pursuant to Rule 424(b)(3) Registration No. 333-275229 PROSPECTUS SUPPLEMENT (to Prospectus dated November 7, 2023) Portage Biotech Inc. 481,581 Ordinary Shares underlying Warrants This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated November 7, 2023 (the “Prospectus”), which forms a part of our Registration Statement on Form F- |
|
| November 26, 2024 |
6-K 1 f6k112624.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission File Number: 001-40086 Portage Biotech Inc. (Translation of registrant's name into English) British Virgin Islands (Jurisdiction of incorpo |
|
| November 26, 2024 |
NOTICE TO READER OF CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS Exhibit 99.1 Portage Biotech Inc. Condensed Consolidated Interim Financial Statements For the Three and Six Months Ended September 30, 2024 and 2023 (Unaudited – Prepared by Management as of November 26, 2024) (Expressed in U.S. Dollars) Portage Biotech Inc. Condensed Consolidated Interim Financial Statements TABLE OF CONTENTS Page No. Notice to Reader F-1 Condensed Consolidated Interim Statements |
|
| November 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission File Number: 001-40086 Portage Biotech Inc. (Translation of registrant’s name into English) Clarence Thomas Building, P.O. Box 4649, Road Town, Tortola, British Virgin |
|
| November 26, 2024 |
EXHIBIT 99.1 Portage Biotech Reports Results for Fiscal Quarter Ended September 30, 2024 Exploration and evaluation of strategic alternatives continue WESTPORT, Conn., Nov. 26, 2024 (GLOBE NEWSWIRE) - Portage Biotech Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of novel multi-targeted therapies for use as monotherapy and in combination |
|
| November 26, 2024 |
Exhibit 99.2 PORTAGE BIOTECH INC. THREE AND SIX MONTHS ENDED SEPTEMBER 30, 2024 MANAGEMENT’S DISCUSSION AND ANALYSIS Prepared as of November 26, 2024 TABLE OF CONTENTS Page No. Forward-Looking Statements 3 Nature of Operations and Overview 3 Summary of Results 6 Number of Ordinary Shares 7 Business Environment – Risk Factors 7 Our Programs and Technology – Recent Developments 8 Results of Operatio |
|
| November 14, 2024 |
PRTG / Portage Biotech Inc. / Bailey Gregory Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3)* Portage Biotech Inc. (Name of Issuer) Ordinary Shares, No Par Value (Title of Class of Securities) G7185A136 |
|
| November 14, 2024 |
PRTG / Portage Biotech Inc. / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| October 4, 2024 |
Portage Biotech Inc. 481,581 Ordinary Shares underlying Warrants Filed Pursuant to Rule 424(b)(3) Registration No. 333-275229 PROSPECTUS SUPPLEMENT (to Prospectus dated November 7, 2023) Portage Biotech Inc. 481,581 Ordinary Shares underlying Warrants This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated November 7, 2023 (the “Prospectus”), which forms a part of our Registration Statement on Form F- |
|
| October 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission File Number: 001-40086 Portage Biotech Inc. (Translation of registrant’s name into English) Clarence Thomas Building, P.O. Box 4649, Road Town, Tortola, British Virgin I |
|
| September 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2024 Commission File Number: 001-40086 Portage Biotech Inc. (Translation of registrant’s name into English) Clarence Thomas Building, P.O. Box 4649, Road Town, Tortola, British Virgi |
|
| September 4, 2024 |
Portage Biotech Inc. 481,581 Ordinary Shares underlying Warrants Filed Pursuant to Rule 424(b)(3) Registration No. 333-275229 PROSPECTUS SUPPLEMENT (to Prospectus dated November 7, 2023) Portage Biotech Inc. 481,581 Ordinary Shares underlying Warrants This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated November 7, 2023 (the “Prospectus”), which forms a part of our Registration Statement on Form F- |
|
| August 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024 Commission File Number: 001-40086 Portage Biotech Inc. (Translation of registrant’s name into English) Clarence Thomas Building, P.O. Box 4649, Road Town, Tortola, British Virgin Is |
|
| August 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024 Commission File Number: 001-40086 Portage Biotech Inc. (Translation of registrant's name into English) British Virgin Islands (Jurisdiction of incorporation or organization) Clarenc |
|
| August 27, 2024 |
NOTICE TO READER OF CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS Exhibit 99.1 Portage Biotech Inc. Condensed Consolidated Interim Financial Statements For the Three Months Ended June 30, 2024 (Unaudited – Prepared by Management as of August 26, 2024) (U.S. Dollars) Portage Biotech Inc. Condensed Consolidated Interim Financial Statements Index Page Notice to Reader F-1 Condensed Consolidated Interim Statements of Financial Position As of June 30, 2024 (Unaudited |
|
| August 27, 2024 |
Portage Biotech Inc. 9,631,580 Ordinary Shares underlying Warrants Filed Pursuant to Rule 424(b)(3) Registration No. 333-275229 PROSPECTUS SUPPLEMENT (to Prospectus dated November 7, 2023) Portage Biotech Inc. 9,631,580 Ordinary Shares underlying Warrants This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated November 7, 2023 (the “Prospectus”), which forms a part of our Registration Statement on Form |
|
| August 27, 2024 |
Exhibit 99.2 PORTAGE BIOTECH INC. THREE MONTHS ENDED JUNE 30, 2024 MANAGEMENT’S DISCUSSION AND ANALYSIS Prepared as of August 26, 2024 TABLE OF CONTENTS Page No. Forward-Looking Statements 3 Nature of Operations and Overview 4 Summary of Results 8 Number of Ordinary Shares 8 Business Environment – Risk Factors 9 Our Programs and Technology – Recent Developments 9 Results of Operations 14 Liquidity |
|
| August 27, 2024 |
EXHIBIT 99.1 Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2024 and Business Update Exploration and evaluation of strategic alternatives continue WESTPORT, Conn., Aug. 27, 2024 (GLOBE NEWSWIRE) - Portage Biotech Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of novel multi-targeted therapies for use as monotherapy and |
|
| August 23, 2024 |
As filed with the Securities and Exchange Commission on August 22, 2024 As filed with the Securities and Exchange Commission on August 22, 2024 Registration No. |
|
| August 15, 2024 |
Portage Biotech Reports Fiscal Year-Ended March 31, 2024 Financial Results and Business Update EXHIBIT 99.1 Portage Biotech Reports Fiscal Year-Ended March 31, 2024 Financial Results and Business Update Exploration and evaluation of strategic alternatives continue Pausing patient enrollment in the ADPORT-601 clinical trial (adenosine 2A and 2B inhibitors) Discontinuing the iNKT clinical trial for PORT-2 WESTPORT, Conn., Aug. 15, 2024 (GLOBE NEWSWIRE) - Portage Biotech Inc. (“Portage” or the |
|
| August 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024 Commission File Number: 001-40086 Portage Biotech Inc. (Translation of registrant's name into English) British Virgin Islands (Jurisdiction of incorporation or organization) Clarenc |
|
| August 15, 2024 |
Portage Biotech Inc. 9,631,580 Ordinary Shares underlying Warrants Filed Pursuant to Rule 424(b)(3) Registration No. 333-275229 PROSPECTUS SUPPLEMENT (to Prospectus dated November 7, 2023) Portage Biotech Inc. 9,631,580 Ordinary Shares underlying Warrants This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated November 7, 2023 (the “Prospectus”), which forms a part of our Registration Statement on Form |
|
| August 14, 2024 |
EXHIBIT 4.28 FIRST AMENDMENT OF LEASE THIS FIRST AMENDMENT OF LEASE (this" Amendment") made as of the U>day of February 2024 , by and between WALP 57 - 61 , LLC with a principal place of business c/o David Adam Realty, Inc . , 57 Wilton Road, Westport, Connecticut 06880 ("Landlord"), and Portage Development Services, LLC, with a place of business at 61 Wilton Road, Westport, Connecticut, 06880 ("T |
|
| August 14, 2024 |
CERTIFICATIONS PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 EXHIBIT 12.1 CERTIFICATIONS PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Dr. Ian Walters, Chairman of the Board and Chief Executive Officer of Portage Biotech Inc., certify that: 1. I have reviewed this Annual Report on Form 20-F of Portage Biotech Inc. for the fiscal year ended March 31, 2024. 2. Based on my knowledge, this report does not contain any untrue statement of a materia |
|
| August 14, 2024 |
EXHIBIT 13.2 CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Allan Shaw, Chief Financial Officer of Portage Biotech Inc. (the “Company”), hereby certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge: (i) t |
|
| August 14, 2024 |
INSIDER TRADING POLICY – PORTAGE BIOTECH INC. EXHIBIT 11.5 INSIDER TRADING POLICY – PORTAGE BIOTECH INC. Policy Under United States securities laws, it is a crime to buy or sell securities of a company (including stocks and bonds) while in possession of material, non-public information about the company. Furthermore, it is a crime to pass on such information to others who use it for personal profit, if the information was obtained in the cour |
|
| August 14, 2024 |
CERTIFICATIONS PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 EXHIBIT 12.2 CERTIFICATIONS PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Allan Shaw, Chief Financial Officer of Portage Biotech Inc., certify that: 1. I have reviewed this Annual Report on Form 20-F of Portage Biotech Inc. for the fiscal year ended March 31, 2024. 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a mater |
|
| August 14, 2024 |
EXHIBIT 13.1 CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Dr. Ian Walters, Chairman of the Board and Chief Executive Officer of Portage Biotech Inc. (the “Company”), hereby certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to |
|
| August 14, 2024 |
INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM’S CONSENT EXHIBIT 15.1 INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM’S CONSENT We consent to the incorporation by reference in the Registration Statement of Portage Biotech Inc. on Form S-8 (File No. 333-275842) of our report dated August 14, 2024, which includes an explanatory paragraph as to the Company’s ability to continue as a going concern, with respect to our audits of the consolidated financial stat |
|
| August 14, 2024 |
Portage Biotech Inc. Incentive Compensation Recovery Policy EXHIBIT 97.1 Portage Biotech Inc. Incentive Compensation Recovery Policy Adopted by the Board of Directors (the “Board”) of Portage Biotech Inc. (the “Company”) on November 8, 2023 The Company, including subsidiaries, is committed to conducting business in accordance with the highest ethical and legal standards, and the Board believes that a culture that emphasizes integrity and accountability is |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1 |
|
| August 13, 2024 |
Portage Biotech Announces 1-for-20 Reverse Stock Split EXHIBIT 99.1 Portage Biotech Announces 1-for-20 Reverse Stock Split WESTPORT, Conn., Aug. 13, 2024 (GLOBE NEWSWIRE) - Portage Biotech Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of novel multi-targeted therapies for use as monotherapy and in combination, today announced that the Company’s Board of Directors approved a reverse stock sp |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024 Commission File Number: 001-40086 Portage Biotech Inc. (Translation of registrant's name into English) British Virgin Islands (Jurisdiction of incorporation or organization) Clarenc |
|
| August 13, 2024 |
Portage Biotech Inc. 9,631,580 Ordinary Shares underlying Warrants Filed Pursuant to Rule 424(b)(3) Registration No. 333-275229 PROSPECTUS SUPPLEMENT (to Prospectus dated November 7, 2023) Portage Biotech Inc. 9,631,580 Ordinary Shares underlying Warrants This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated November 7, 2023 (the “Prospectus”), which forms a part of our Registration Statement on Form |
|
| August 1, 2024 |
Portage Biotech Inc. 9,631,580 Ordinary Shares underlying Warrants Filed Pursuant to Rule 424(b)(3) Registration No. 333-275229 PROSPECTUS SUPPLEMENT (to Prospectus dated November 7, 2023) Portage Biotech Inc. 9,631,580 Ordinary Shares underlying Warrants This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated November 7, 2023 (the “Prospectus”), which forms a part of our Registration Statement on Form |
|
| August 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER: 001-40086 CUSIP NUMBER: G7185A128 (Check one): ☐ Form 10-K ☒ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: March 31, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Tran |
|
| May 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2024 Commission File Number: 001-40086 Portage Biotech Inc. (Translation of registrant’s name into English) Clarence Thomas Building, P.O. Box 4649, Road Town, Tortola, British Virgin Is |
|
| May 1, 2024 |
Portage Biotech Inc. 9,631,580 Ordinary Shares underlying Warrants Filed Pursuant to Rule 424(b)(3) Registration No. 333-275229 PROSPECTUS SUPPLEMENT (to Prospectus dated November 7, 2023) Portage Biotech Inc. 9,631,580 Ordinary Shares underlying Warrants This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated November 7, 2023 (the “Prospectus”), which forms a part of our Registration Statement on Form |
|
| April 12, 2024 |
Portage Biotech Inc. 9,631,580 Ordinary Shares underlying Warrants Filed Pursuant to Rule 424(b)(3) Registration No. 333-275229 PROSPECTUS SUPPLEMENT (to Prospectus dated November 7, 2023) Portage Biotech Inc. 9,631,580 Ordinary Shares underlying Warrants This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated November 7, 2023 (the “Prospectus”), which forms a part of our Registration Statement on Form |
|
| April 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File Number: 001-40086 Portage Biotech Inc. (Translation of registrant's name into English) British Virgin Islands (Jurisdiction of incorporation or organization) Clarence |
|
| April 12, 2024 |
EXHIBIT 99.1 Portage Biotech Announces Plans to Expand its Evaluation of Strategic Alternatives -Adenosine clinical development paused WESTPORT, Conn., April 12, 2024 (GLOBE NEWSWIRE) - Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today reported that it is expanding its evaluation o |
|
| March 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2024 Commission File Number: 001-40086 Portage Biotech Inc. (Translation of registrant’s name into English) Clarence Thomas Building, P.O. Box 4649, Road Town, Tortola, British Virgin Is |
|
| March 8, 2024 |
Portage Biotech Inc. 9,631,580 Ordinary Shares underlying Warrants Filed Pursuant to Rule 424(b)(3) Registration No. 333-275229 PROSPECTUS SUPPLEMENT (to Prospectus dated November 7, 2023) Portage Biotech Inc. 9,631,580 Ordinary Shares underlying Warrants This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated November 7, 2023 (the “Prospectus”), which forms a part of our Registration Statement on Form |
|
| March 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 Commission File Number: 001-40086 Portage Biotech Inc. (Translation of registrant’s name into English) N/A (Translation of registrant’s name into English) British Virgin Islands (Jur |
|
| March 7, 2024 |
Portage Biotech Inc. 9,631,580 Ordinary Shares underlying Warrants Filed Pursuant to Rule 424(b)(3) Registration No. 333-275229 PROSPECTUS SUPPLEMENT (to Prospectus dated November 7, 2023) Portage Biotech Inc. 9,631,580 Ordinary Shares underlying Warrants This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated November 7, 2023 (the “Prospectus”), which forms a part of our Registration Statement on Form |
|
| March 7, 2024 |
Exhibit 99.1 1 Corporate Presentation Nasdaq: PRTG March 2024 2 Legal Disclaimer Forward - Looking Information This presentation contains forward - looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995 . Statements in this presentation that are not statements of historical fact are forward - looking statements . Words such as “may,” “will,” “sh |
|
| February 29, 2024 |
EXHIBIT 99.1 Portage Biotech Reports Results for Fiscal Quarter Ended December 31, 2023, and Business Update Company focused on adenosine platform clinical development WESTPORT, Conn., Feb. 28, 2024 (GLOBE NEWSWIRE) - Portage Biotech Inc. (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in comb |
|
| February 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2024 Commission File Number: 001-40086 Portage Biotech Inc. (Translation of registrant's name into English) British Virgin Islands (Jurisdiction of incorporation or organization) Clare |
|
| February 28, 2024 |
Exhibit 99.1 Portage Biotech Inc. Condensed Consolidated Interim Financial Statements For the Three and Nine Months Ended December 31, 2023 (Unaudited – Prepared by Management as of February 28, 2024) (U.S. Dollars) Portage Biotech Inc. Condensed Consolidated Interim Financial Statements Index Page Notice to Reader F-1 Condensed Consolidated Interim Statements of Financial Position As of December |
|
| February 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2024 Commission File Number: 001-40086 Portage Biotech Inc. (Translation of registrant’s name into English) Clarence Thomas Building, P.O. Box 4649, Road Town, Tortola, British Virgin |
|
| February 28, 2024 |
Exhibit 99.2 PORTAGE BIOTECH INC. THREE AND NINE MONTHS ENDED DECEMBER 31, 2023 MANAGEMENT’S DISCUSSION AND ANALYSIS Prepared as of February 28, 2024 TABLE OF CONTENTS Page No. Forward-Looking Statements 3 Nature of Operations and Overview 4 Summary of Results 8 Number of Ordinary Shares 8 Business Environment – Risk Factors 9 Our Programs and Technology – Recent Developments 9 Results of Operatio |
|
| February 28, 2024 |
Portage Biotech Inc. 9,631,580 Ordinary Shares underlying Warrants Filed Pursuant to Rule 424(b)(3) Registration No. 333-275229 PROSPECTUS SUPPLEMENT (to Prospectus dated November 7, 2023) Portage Biotech Inc. 9,631,580 Ordinary Shares underlying Warrants This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated November 7, 2023 (the “Prospectus”), which forms a part of our Registration Statement on Form |
|
| February 14, 2024 |
PRTG / Portage Biotech Inc. / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| January 19, 2024 |
Portage Biotech Inc. 9,631,580 Ordinary Shares underlying Warrants Filed Pursuant to Rule 424(b)(3) Registration No. 333-275229 PROSPECTUS SUPPLEMENT (to Prospectus dated November 7, 2023) Portage Biotech Inc. 9,631,580 Ordinary Shares underlying Warrants This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated November 7, 2023 (the “Prospectus”), which forms a part of our Registration Statement on Form |
|
| January 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2024 Commission File Number: 001-40086 Portage Biotech Inc. (Translation of registrant’s name into English) N/A (Translation of registrant’s name into English) British Virgin Islands (J |
|
| January 18, 2024 |
Exhibit 99.1 1 Corporate Presentation Nasdaq: PRTG January 2024 2 Legal Disclaimer Forward - Looking Information This presentation contains forward - looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995 . Statements in this presentation that are not statements of historical fact are forward - looking statements . Words such as “may,” “will,” “ |
|
| January 5, 2024 |
Portage Biotech Inc. 9,631,580 Ordinary Shares underlying Warrants Filed Pursuant to Rule 424(b)(3) Registration No. 333-275229 PROSPECTUS SUPPLEMENT (to Prospectus dated November 7, 2023) Portage Biotech Inc. 9,631,580 Ordinary Shares underlying Warrants This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated November 7, 2023 (the “Prospectus”), which forms a part of our Registration Statement on Form |
|
| January 4, 2024 |
EXHIBIT 99.1 Portage Biotech Reports Business and Strategic Update • Prioritize the adenosine clinical candidates • iNKT clinical development paused to focus resources • Company will evaluate range of strategic options WESTPORT, Conn., Jan. 04, 2024 (GLOBE NEWSWIRE) - Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as m |
|
| January 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2024 Commission File Number: 001-40086 Portage Biotech Inc. (Translation of registrant's name into English) British Virgin Islands (Jurisdiction of incorporation or organization) Claren |
|
| December 1, 2023 |
PORTAGE BIOTECH INC. AMENDED AND RESTATED 2021 EQUITY INCENTIVE PLAN Exhibit 4.2 PORTAGE BIOTECH INC. AMENDED AND RESTATED 2021 EQUITY INCENTIVE PLAN 1. Purposes of the Plan. This Plan is an amendment and restatement, effective as of the 2022 Amendment Date, of the Portage Biotech Inc. 2021 Equity Incentive Plan. The purpose of this Plan is to develop the interest of the directors, officers, employees and consultants who provide on-going services to the Company and |
|
| December 1, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Portage Biotech Inc. |
|
| December 1, 2023 |
As filed with the Securities and Exchange Commission on December 1, 2023 As filed with the Securities and Exchange Commission on December 1, 2023 Registration No. |
|
| November 28, 2023 |
EXHIBIT 99.1 Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2023, and Business Update PORT 2 and 6 Presented at the Society for Immunotherapy of Cancer’s (SITC) Annual Meeting WESTPORT, Conn., Nov. 28, 2023 (GLOBE NEWSWIRE) - Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combin |
|
| November 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023 Commission File Number: 001-40086 Portage Biotech Inc. (Translation of registrant's name into English) British Virgin Islands (Jurisdiction of incorporation or organization) Clare |
|
| November 28, 2023 |
Exhibit 99.1 Portage Biotech Inc. Condensed Consolidated Interim Financial Statements For the Three and Six Months Ended September 30, 2023 (Unaudited – Prepared by Management as of November 28, 2023) (U.S. Dollars) Portage Biotech Inc. Condensed Consolidated Interim Financial Statements Index Page Notice to Reader F-1 Condensed Consolidated Interim Statements of Financial Position As of September |
|
| November 28, 2023 |
Exhibit 99.2 PORTAGE BIOTECH INC. THREE AND SIX MONTHS ENDED SEPTEMBER 30, 2023 MANAGEMENT’S DISCUSSION AND ANALYSIS Prepared as of November 28, 2023 TABLE OF CONTENTS Page No. Forward-Looking Statements 3 Nature of Operations and Overview 4 Summary of Results 8 Number of Ordinary Shares 8 Business Environment – Risk Factors 9 Our Programs and Technology – Recent Developments 9 Results of Operatio |
|
| November 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023 Commission File Number: 001-40086 Portage Biotech Inc. (Translation of registrant’s name into English) Clarence Thomas Building, P.O. Box 4649, Road Town, Tortola, British Virgin |
|
| November 28, 2023 |
Portage Biotech Inc. 9,631,580 Ordinary Shares underlying Warrants Filed Pursuant to Rule 424(b)(3) Registration No. 333-275229 PROSPECTUS SUPPLEMENT (to Prospectus dated November 7, 2023) Portage Biotech Inc. 9,631,580 Ordinary Shares underlying Warrants This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated November 7, 2023 (the “Prospectus”), which forms a part of our Registration Statement on Form |
|
| November 14, 2023 |
Portage Biotech Inc. 9,631,580 Ordinary Shares underlying Warrants Filed Pursuant to Rule 424(b)(3) Registration No. 333-275229 PROSPECTUS SUPPLEMENT (to Prospectus dated November 7, 2023) Portage Biotech Inc. 9,631,580 Ordinary Shares underlying Warrants This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated November 7, 2023 (the “Prospectus”), which forms a part of our Registration Statement on Form |
|
| November 13, 2023 |
Exhibit 99.1 1 Corporate Presentation Nasdaq: PRTG November 2023 2 Legal Disclaimer Forward - Looking Information This presentation contains "forward - looking statements" that involve risks and uncertainties . Our actual results could differ materially from those discussed in the forward - looking statements . The statements contained in this presentation that are not purely historical are forwar |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023 Commission File Number: 001-40086 Portage Biotech Inc. (Translation of registrant’s name into English) N/A (Translation of registrant’s name into English) British Virgin Islands ( |
|
| November 7, 2023 |
Portage Biotech Inc. 9,631,580 Ordinary Shares underlying Warrants Filed pursuant to Rule 424(b)(3) Registration No. 333-275229 PROSPECTUS Portage Biotech Inc. 9,631,580 Ordinary Shares underlying Warrants The selling shareholders (the “Selling Shareholders”) named in this prospectus may use this prospectus to offer and resell from time to time up to 9,631,580 of our ordinary shares, no par value per share, consisting of (i) up to 3,157,895 ordinary shares (the “ |
|
| November 3, 2023 |
PORTAGE BIOTECH INC. Clarence Thomas Building, P.O. Box 4649 Road Town, Tortola British Virgin Islands, VG1110 November 3, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporate Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Dillon Hagius Re: Portage Biotech Inc. Registration Statement on Form F-1 Filed October 31, 2023 File No. 333-275229 Request for Acceleration of |
|
| October 31, 2023 |
As filed with the Securities and Exchange Commission on October 31, 2023 As filed with the Securities and Exchange Commission on October 31, 2023 Registration No. |
|
| October 31, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form F-1 (Form Type) Portage Biotech Inc. |
|
| October 3, 2023 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of September 29, 2023, between Portage Biotech Inc., a British Virgin Islands company (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and |
|
| October 3, 2023 |
PRE-FUNDED ORDINARY SHARE PURCHASE WARRANT PORTAGE BIOTECH INC. Exhibit 4.1 PRE-FUNDED ORDINARY SHARE PURCHASE WARRANT PORTAGE BIOTECH INC. Warrant Shares: Issue Date:, 2023 Initial Exercise Date: , 2023 THIS PRE-FUNDED ORDINARY SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or |
|
| October 3, 2023 |
Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-253468 PROSPECTUS SUPPLEMENT (To Prospectus dated March 8, 2021) Portage Biotech Inc. 1,970,000 Ordinary Shares Pre-Funded Warrants to Purchase up to 1,187,895 Ordinary Shares 1,187,895 Ordinary Shares Underlying the Pre-Funded Warrants We are offering to an institutional and accredited investor pursuant to this prospectus supplement |
|
| October 3, 2023 |
Exhibit 107 The prospectus supplement to which this exhibit is attached is a final prospectus for the related offering. The maximum aggregate offering price of such offering is $5,998,812.61. |
|
| October 3, 2023 |
SERIES A ORDINARY SHARE PURCHASE WARRANT Portage Biotech Inc. Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| October 3, 2023 |
SERIES B ORDINARY SHARE PURCHASE WARRANT Portage Biotech Inc. Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| October 3, 2023 |
SERIES C ORDINARY SHARE PURCHASE WARRANT Portage Biotech Inc. Exhibit 4.4 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| October 3, 2023 |
PLACEMENT AGENT ORDINARY SHARE PURCHASE WARRANT Portage Biotech Inc. Exhibit 4.5 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| October 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2023 Commission File Number: 001-40086 Portage Biotech Inc. (Translation of registrant’s name into English) Clarence Thomas Building, P.O. Box 4649, Road Town, Tortola, British Virgin |
|
| September 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2023 Commission File Number: 001-40086 Portage Biotech Inc. (Translation of registrant's name into English) British Virgin Islands (Jurisdiction of incorporation or organization) Clar |
|
| September 29, 2023 |
Portage Biotech Announces $6.0 Million Registered Direct Offering EXHIBIT 99.1 Portage Biotech Announces $6.0 Million Registered Direct Offering WESTPORT, Conn., Sept. 29, 2023 (GLOBE NEWSWIRE) - Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents and in combination, today announced that it has entered into a definitive agreement for the purchase and sale in a registered |
|
| September 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2023 Commission File Number: 001-40086 Portage Biotech Inc. (Translation of registrant’s name into English) N/A (Translation of registrant’s name into English) British Virgin Islands |
|
| September 8, 2023 |
Exhibit 99.1 1 Corporate Presentation Nasdaq: PRTG September 2023 2 Legal Disclaimer This presentation is for information purposes only. This presentation does not constitute a general advertisement or general solicitation or an offer to sell or a solicitation to buy any securities in any jurisdiction. Such an offer can only be made by prospectus or other authorized offering document. This present |
|
| August 30, 2023 |
EdgarFiling EXHIBIT 99.1 Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2023 and Business Update Company focused on accelerating clinical programs for PORT-2, PORT-6, and PORT-7 WESTPORT, Conn., Aug. 30, 2023 (GLOBE NEWSWIRE) - Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in comb |
|
| August 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023 Commission File Number: 001-40086 Portage Biotech Inc. (Translation of registrant's name into English) British Virgin Islands (Jurisdiction of incorporation or organization) Clarenc |
|
| August 29, 2023 |
Exhibit 99.2 PORTAGE BIOTECH INC. THREE MONTHS ENDED JUNE 30, 2023 MANAGEMENT’S DISCUSSION AND ANALYSIS Prepared as of August 29, 2023 TABLE OF CONTENTS Page No. Forward-Looking Statements 3 Nature of Operations and Overview 4 Summary of Results 8 Number of Ordinary Shares 8 Business Environment – Risk Factors 9 Our Programs and Technology – Recent Developments 9 Results of Operations 15 Liquidity |
|
| August 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023 Commission File Number: 001-40086 Portage Biotech Inc. (Translation of registrant’s name into English) Clarence Thomas Building, P.O. Box 4649, Road Town, Tortola, British Virgin Is |
|
| August 29, 2023 |
Exhibit 99.1 Portage Biotech Inc. Condensed Consolidated Interim Financial Statements For the Three Months Ended June 30, 2023 (Unaudited – Prepared by Management as of August 29, 2023) (U.S. Dollars) Portage Biotech Inc. Condensed Consolidated Interim Financial Statements Index Page Notice to Reader F-1 Condensed Consolidated Interim Statements of Financial Position As of June 30, 2023 (Unaudited |
|
| August 14, 2023 |
Exhibit 99.1 Corporate Presentation 1 Nasdaq: PRTG August 2023 Legal Disclaimer 2 This presentation is for information purposes only . This presentation does not constitute a general advertisement or general solicitation or an offer to sell or a solicitation to buy any securities in any jurisdiction . Such an offer can only be made by prospectus or other authorized offering document . This present |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023 Commission File Number: 001-40086 Portage Biotech Inc. (Translation of registrant’s name into English) N/A (Translation of registrant’s name into English) British Virgin Islands (Ju |
|
| August 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2023 Commission File Number: 001-40086 Portage Biotech Inc. (Translation of registrant's name into English) British Virgin Islands (Jurisdiction of incorporation or organization) Clarence |
|
| August 1, 2023 |
Portage Biotech Reports Fiscal Year-Ended March 31, 2023 Financial Results and Business Update EdgarFiling EXHIBIT 99.1 Portage Biotech Reports Fiscal Year-Ended March 31, 2023 Financial Results and Business Update Company poised to accelerate accrual in all clinical programs as it activates numerous sites across multiple U.S. cities and abroad and takes over sponsorship from the investigator-led program Updated interim data for lead iNKT engager, PORT-2, presented at the 2023 ASCO Annual M |
|
| July 31, 2023 |
Exhibit 4.29 OFFICE LEASE by and between WALP 57 - 61, LLC (Landlord) and Portage Development Services, Inc. (Tenant) Dated: March 31, 2023 TABLE OF CONTENTS 1. PREMISES ............................................................................................................. 2. ORIGINAL TERM ................................................................................................. 3. RE |
|
| July 31, 2023 |
CERTIFICATIONS PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 EXHIBIT 12.1 CERTIFICATIONS PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Dr. Ian Walters, Chairman of the Board and Chief Executive Officer of Portage Biotech Inc., certify that: 1. I have reviewed this Annual Report on Form 20-F of Portage Biotech Inc. for the fiscal year ended March 31, 2023. 2. Based on my knowledge, this report does not contain any untrue statement of a materia |
|
| July 31, 2023 |
PORTAGE BIOTECH INC. 2021 EQUITY INCENTIVE PLAN Share Option Agreement EXHIBIT 4.28 PORTAGE BIOTECH INC. 2021 EQUITY INCENTIVE PLAN Share Option Agreement This Share Option Agreement (this “Agreement”), dated as of the Grant Date, is between Portage Biotech Inc., a corporation formed under the laws of the Territory of the British Virgin Islands (the “Company”), and (the “Optionee”). The Company hereby grants to the Optionee the following option (the “Option”) to purc |
|
| July 31, 2023 |
PORTAGE BIOTECH INC. 2021 EQUITY INCENTIVE PLAN Share Option Agreement EXHIBIT 4.27 PORTAGE BIOTECH INC. 2021 EQUITY INCENTIVE PLAN Share Option Agreement This Share Option Agreement (this “Agreement”), dated as of the Grant Date, is between Portage Biotech Inc., a corporation formed under the laws of the Territory of the British Virgin Islands (the “Company”), and (the “Optionee”). The Company hereby grants to the Optionee the following option (the “Option”) to purc |
|
| July 31, 2023 |
Exhibit 4.24 SERVICES AGREEMENT THIS SERVICES AGREEMENT (the “ Agreement ”) is effective as of June 1 , 2022 , by and between Portage Development Services Inc . , a Delaware corporation (the “Company”), and Justin Fairchild a resident of the State of Connecticut (the “ Executive ”) . WHEREAS , the Company and Executive desire to enter into this Agreement pursuant to which the Company will continue |
|
| July 31, 2023 |
EXHIBIT 13.1 CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Dr. Ian Walters, Chairman of the Board and Chief Executive Officer of Portage Biotech Inc. (the “Company”), hereby certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to |
|
| July 31, 2023 |
EXHIBIT 13.2 CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Allan Shaw, Chief Financial Officer of Portage Biotech Inc. (the “Company”), hereby certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge: (i) t |
|
| July 31, 2023 |
Exhibit 4.25 CLINICAL SERVICES AGREEMENT This CLINICAL SERVICES AGREEMENT (this “ Agreement ”) is made effective as of the date of last signature below (the “ Effective Date ”) by and between Labcorp Drug Development Inc . with a place of business at 10 Moore Drive, Durham, NC 27709 which, together with its Affiliates, is referred to in this Agreement as “ Labcorp ” ; and TARUS THERAPEUTICS LLC, w |
|
| July 31, 2023 |
PORTAGE BIOTECH INC. 2021 EQUITY INCENTIVE PLAN Share Option Agreement EXHIBIT 4.26 PORTAGE BIOTECH INC. 2021 EQUITY INCENTIVE PLAN Share Option Agreement This Share Option Agreement (this “Agreement”), dated as of the Grant Date, is between Portage Biotech Inc., a corporation formed under the laws of the Territory of the British Virgin Islands (the “Company”), and (the “Optionee”). The Company hereby grants to the Optionee the following option (the “Option”) to purc |
|
| July 31, 2023 |
Exhibit 4.30 CERTAIN IDENTIFIED INFORMATION, MARKED WITH “[****]”, HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. LICENSE AGREEMENT This License Agreement (this “Agreement”), dated as of July 1, 2015 (the “Effective Date”), is made by and between iOx Therapeutics Ltd., a company registered in Engla |
|
| July 31, 2023 |
Exhibit 4.31 CERTAIN IDENTIFIED INFORMATION, MARKED WITH “[****]”, HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. LICENSE AGREEMENT This License Agreement (this “Agreement”) is entered into as of October 29, 2019 (the “Agreement Date”), by and between Tarus Therapeutics, Inc., a company formed unde |
|
| July 31, 2023 |
CERTIFICATIONS PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 EXHIBIT 12.2 CERTIFICATIONS PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Allan Shaw, Chief Financial Officer of Portage Biotech Inc., certify that: 1. I have reviewed this Annual Report on Form 20-F of Portage Biotech Inc. for the fiscal year ended March 31, 2023. 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a mater |
|
| July 31, 2023 |
Portage Biotech, Inc. Audit Committee Charter Exhibit 11.1 Portage Biotech, Inc. Audit Committee Charter I. PURPOSE The Audit Committee shall provide assistance to the Board of Directors (the “Board”) of Portage Biotech, Inc. (the “Corporation”) in fulfilling the Board’s responsibility to the Corporation’s shareholders relating to the Corporation’s accounting, financial reporting practices, the system of internal control, the audit process, t |
|
| July 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1 |
|
| July 31, 2023 |
PORTAGE BIOTECH, INC. COMPENSATION COMMITTEE CHARTER Exhibit 11.2 PORTAGE BIOTECH, INC. COMPENSATION COMMITTEE CHARTER I. Purpose The purpose of the compensation committee (the “Committee”) of the Board of Directors (the “Board”) of Portage Biotech, Inc. (the “Company”) is to (a) assist the Board in fulfilling its responsibilities regarding the compensation of the Company’s Chief Executive Officer (the “CEO”), the Company’s other executive officers, |
|
| July 31, 2023 |
Independent Registered Public Accounting Firm’s Consent Exhibit 15.1 Independent Registered Public Accounting Firm’s Consent We consent to the incorporation by reference in the Registration Statement of Portage Biotech Inc. on Form F-3 (File No. 333-253468) of our report dated July 31, 2023, which includes an explanatory paragraph as to the Company’s ability to continue as a going concern, with respect to our audits of the consolidated financial statem |
|
| June 21, 2023 |
Exhibit 99.1 1 Corporate Presentation Nasdaq: PRTG June 2023 2 Legal Disclaimer This presentation is for information purposes only . This presentation does not constitute a general advertisement or general solicitation or an offer to sell or a solicitation to buy any securities in any jurisdiction . Such an offer can only be made by prospectus or other authorized offering document . This presentat |
|
| June 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2023 Commission File Number: 001-40086 Portage Biotech Inc. (Translation of registrant’s name into English) N/A (Translation of registrant’s name into English) British Virgin Islands (Juri |
|
| May 1, 2023 |
Exhibit 99.1 1 Corporate Presentation Nasdaq: PRTG May 2023 2 Legal Disclaimer This presentation is for information purposes only . This presentation does not constitute a general advertisement or general solicitation or an offer to sell or a solicitation to buy any securities in any jurisdiction . Such an offer can only be made by prospectus or other authorized offering document . This presentati |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission File Number: 001-40086 Portage Biotech Inc. (Translation of registrant’s name into English) N/A (Translation of registrant’s name into English) British Virgin Islands (Juris |
|
| March 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 Commission File Number: 001-40086 Portage Biotech Inc. (Translation of registrant’s name into English) N/A (Translation of registrant’s name into English) British Virgin Islands (Jur |
|
| March 14, 2023 |
Exhibit 99.1 Corporate Presentation 1 Nasdaq: PRTG March 2023 Legal Disclaimer 2 This presentation is for information purposes only . This presentation does not constitute a general advertisement or general solicitation or an offer to sell or a solicitation to buy any securities in any jurisdiction . Such an offer can only be made by prospectus or other authorized offering document . This presenta |
|
| March 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 December 31, 2022 Commission File Number: 001-40086 Portage Biotech Inc. (Translation of registrant’s name into English) Clarence Thomas Building, P.O. Box 4649, Road Town, Tortola, |
|
| March 1, 2023 |
Exhibit 99.1 Portage Biotech Inc. Condensed Consolidated Interim Financial Statements For the Three and Nine Months Ended December 31, 2022 (Unaudited – Prepared by Management as of March 1, 2023) (U.S. Dollars) Portage Biotech Inc. Condensed Consolidated Interim Financial Statements Index Page Notice to Reader F-1 Condensed Consolidated Interim Statements of Financial Position As of December 31, |
|
| March 1, 2023 |
Exhibit 99.2 PORTAGE BIOTECH INC. THREE AND NINE MONTHS ENDED DECEMBER 31, 2022 MANAGEMENT’S DISCUSSION AND ANALYSIS Prepared as of March 1, 2023 Index Forward-Looking Statements 3 Nature of Operations and Overview 4 Summary of Results 8 Number of Ordinary Shares and Warrants 8 Business Environment – Risk Factors 9 Our Programs and Technology – Recent Developments 9 Results of Operations 14 Liquid |
|
| January 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2023 Commission File Number: 001-40086 Portage Biotech Inc. (Translation of registrant?s name into English) N/A (Translation of registrant?s name into English) British Virgin Islands (J |
|
| January 6, 2023 |
EX-99.1 2 exh991.htm EXHIBIT 99.1 Exhibit 99.1 1 Corporate Presentation Nasdaq: PRTG January 2023 2 Legal Disclaimer This presentation is for information purposes only . This presentation does not constitute a general advertisement or general solicitation or an offer to sell or a solicitation to buy any securities in any jurisdiction . Such an offer can only be made by prospectus or other authoriz |
|
| December 1, 2022 |
Exhibit 99.1 Corporate Presentation 1 Nasdaq: PRTG December 2022 Legal Disclaimer 2 This presentation is for information purposes only . This presentation does not constitute a general advertisement or general solicitation or an offer to sell or a solicitation to buy any securities in any jurisdiction . Such an offer can only be made by prospectus or other authorized offering document . This prese |
|
| December 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022 Commission File Number: 001-40086 Portage Biotech Inc. (Translation of registrant’s name into English) N/A (Translation of registrant’s name into English) British Virgin Islands ( |
|
| November 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022 Commission File Number: 001-40086 Portage Biotech Inc. (Translation of registrant?s name into English) N/A (Translation of registrant?s name into English) British Virgin Islands ( |
|
| November 29, 2022 |
Exhibit 99.2 PORTAGE BIOTECH INC. THREE AND SIX MONTHS ENDED SEPTEMBER 30, 2022 MANAGEMENT?S DISCUSSION AND ANALYSIS Prepared as of November 29, 2022 Index Forward-Looking Statements 3 Nature of Operations and Overview 4 Summary of Results 8 Number of Ordinary Shares and Warrants 8 Business Environment ? Risk Factors 9 Our Programs and Technology ? Recent Developments 9 Results of Operations 14 Li |
|
| November 29, 2022 |
Exhibit 99.1 Portage Biotech Inc. Condensed Consolidated Interim Financial Statements For the Three and Six Months Ended September 30, 2022 (Unaudited – Prepared by Management) as of November 29, 2022 (U.S. Dollars) Portage Biotech Inc. Condensed Consolidated Interim Financial Statements Index Page Notice to Reader F-1 Condensed Consolidated Interim Statements of Financial Position As of September |
|
| November 15, 2022 |
6-K 1 f6k111522.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of: November 2022 Commission File Number: 001-40086 Portage Biotech Inc. (Translation of registrant’s name into English) British Virgin Island (Jurisdiction of incorpo |
|
| November 9, 2022 |
EXHIBIT 99.1 Portage Biotech Announces Clinical Trial Collaboration Agreement with Merck Study will evaluate PORT-2 in combination with KEYTRUDA? (pembrolizumab) for the treatment of patients with front-line as well as refractory non-small cell lung cancer (NSCLC) WESTPORT, Conn., Nov. 08, 2022 (GLOBE NEWSWIRE) - Portage Biotech Inc., (NASDAQ: PRTG) (?Portage? or the ?Company?), a clinical-stage i |
|
| November 9, 2022 |
6-K 1 f6k110922.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022 Commission File Number: 001-40086 Portage Biotech Inc. (Translation of registrant's name into English) British Virgin Islands (Jurisdiction of incorpo |
|
| October 13, 2022 |
Exhibit 99.3 TARUS THERAPEUTICS, INC. INDEX TO FINANCIAL STATEMENTS Page Unaudited Financial Statements Statement of Financial Position as of June 30, 2022 1 Statements of Comprehensive Loss for the Three and Six Months Ended June 30, 2022 and 2021 2 Statements of Cash Flows for the Six Months Ended June 30, 2022 and 2021 3 Notes to the Financial Statements 4 TARUS THERAPEUTICS, INC. Statement of |
|
| October 13, 2022 |
Exhibit 99.4 UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL STATEMENTS The unaudited pro forma condensed consolidated financial statements for the periods indicated below give effect to our acquisition of Tarus Therapeutics, Inc. (?Tarus?), which we consummated on July 1, 2022. The unaudited pro forma condensed consolidated statements of operations for the year ended March 31, 2022 and for t |
|
| October 13, 2022 |
Exhibit 99.2 TARUS THERAPEUTICS, INC. INDEX TO FINANCIAL STATEMENTS Page Unaudited Financial Statements Statement of Financial Position as of March 31, 2022 1 Statements of Comprehensive Loss for the Three Months Ended March 31, 2022 and 2021 2 Statements of Cash Flows for the Three Months Ended March 31, 2022 and 2021 3 Notes to the Financial Statements 4 TARUS THERAPEUTICS, INC. Statement of Fin |
|
| October 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K/A REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2022 Commission File Number: 001-40086 Portage Biotech Inc. (Translation of registrant's name into English) British Virgin Islands (Jurisdiction of incorporation or organization) Cl |
|
| October 13, 2022 |
Exhibit 99.1 Tarus Therapeutics, Inc. Financial Statements December 31, 2021, 2020 and 2019 Tarus Therapeutics, Inc. Financial Statements for the years ended December 31, 2021, 2020, and 2019 (U.S. Dollars) Table of Contents Page Report of Independent Registered Public Accounting Firm 1 - 2 Statements of Financial Position 3 Statements of Comprehensive Loss 4 Statements of Stockholders' Deficit 5 |
|
| October 7, 2022 |
Form of Proxy for electronic voting of ordinary shares Exhibit 99.3 |
|
| October 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of: October 2022 Commission File Number: 001-40086 Portage Biotech Inc. (Translation of registrant?s name into English) British Virgin Island (Jurisdiction of incorporation or organization) Claren |
|
| October 7, 2022 |
Exhibit 99.2 |
|
| October 7, 2022 |
Exhibit 99.4 |
|
| October 7, 2022 |
Exhibit 99.1 NOTICE OF ANNUAL GENERAL MEETING PORTAGE BIOTECH INC. c/o Portage Development Services Inc. 61 Wilton Road, Westport, Connecticut 06880 Notice of Annual General Meeting Notice is hereby given that the Annual General Meeting (Meeting) of PORTAGE BIOTECH INC. (Company) will be held on November 10, 2022 at 10:30 A.M. United States Eastern Standard Time. You may attend the meeting in pers |
|
| September 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2022 Commission File Number: 001-40086 Portage Biotech Inc. (Translation of registrant?s name into English) N/A (Translation of registrant?s name into English) British Virgin Islands |
|
| September 22, 2022 |
Form of updated Articles of Association as of September 20, 2022 Exhibit 4.1 TERRITORY OF THE BRITISH VIRGIN ISLANDS THE BVI BUSINESS COMPANIES ACT, 2004 MEMORANDUM OF ASSOCIATION AND ARTICLES OF ASSOCIATION OF PORTAGE BIOTECH INC. Incorporated on 9 April 1973 in the Province of Ontario, Canada as Kamlo Gold Mines Limited and continued as a BVI Business Company on 5 July 2013 Amended and Restated on 25 July 2017 Amended and Restated on 20 June 2022 Amended and |
|
| September 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2022 Commission File Number: 001-40086 Portage Biotech Inc. (Translation of registrant?s name into English) N/A (Translation of registrant?s name into English) British Virgin Islands |
|
| September 14, 2022 |
EX-99.1 2 exh991.htm EXHIBIT 99.1 Exhibit 99.1 Corporate Presentation 1 Nasdaq: PRTG September 2022 Legal Disclaimer 2 This presentation is for information purposes only . This presentation does not constitute a general advertisement or general solicitation or an offer to sell or a solicitation to buy any securities in any jurisdiction . Such an offer can only be made by prospectus or other author |
|
| August 29, 2022 |
Exhibit 99.1 Portage Biotech Inc. Condensed Consolidated Interim Financial Statements For the Three Months Ended June 30, 2022 (Unaudited ? Prepared by Management) (U.S. Dollars) March 31 Portage Biotech Inc. Condensed Consolidated Interim Financial Statements Index Page Notice to Reader F-1 Condensed Consolidated Interim Statements of Financial Position As of June 30, 2022 (Unaudited) and March 3 |
|
| August 29, 2022 |
EX-99.2 3 exh992.htm EXHIBIT 99.2 Exhibit 99.2 PORTAGE BIOTECH INC. THREE MONTHS ENDED JUNE 30, 2022 MANAGEMENT’S DISCUSSION AND ANALYSIS Prepared as of August 29, 2022 Index Forward-Looking Statements 3 Nature of Operations and Overview 4 Summary of Results 8 Number of Ordinary Shares and Warrants 8 Business Environment - Risk Factors 8 Our Programs and Technology - Recent Developments 9 Results |
|
| August 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2022 June 30, 2022 Commission File Number: 0-30314 Portage Biotech Inc. (Translation of registrant?s name into English) N/A (Translation of registrant?s name into English) British Virgin |
|
| August 19, 2022 |
PORTAGE BIOTECH INC. Up to $30,000,000 Ordinary Shares 424B5 1 f424b5081722.htm 424B5 Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-253468 PROSPECTUS SUPPLEMENT (to Prospectus dated March 8, 2021) PORTAGE BIOTECH INC. Up to $30,000,000 and 94,508 Ordinary Shares We have entered into a purchase agreement, or Purchase Agreement, dated July 6, 2022, with Lincoln Park Capital Fund, LLC, or Lincoln Park, related to the issuance and sale o |
|
| August 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of: August 2022 Commission File Number: 000-30314 Portage Biotech Inc. (Translation of registrant?s name into English) British Virgin Island (Jurisdiction of incorporation or organization) 6 Adela |
|
| August 1, 2022 |
EXHIBIT 10.8 C&B Comments 01-24-21 SERVICES AGREEMENT THIS SERVICES AGREEMENT (the ?Agreement?) is effective as of December 15, 2021, by and between Portage Development Services Inc., a Delaware corporation (the ?Company?), and Steve Innaimo a resident of the State of Connecticut (the ?Executive?). WHEREAS, the Company and Executive desire to enter into this Agreement pursuant to which the Company |
|
| August 1, 2022 |
EXHIBIT 12.2 CERTIFICATIONS PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Allan Shaw, Chief Financial Officer of Portage Biotech Inc., certify that: 1. I have reviewed this Annual Report on Form 20-F of Portage Biotech Inc. for the fiscal year ended March 31, 2022. 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a mater |
|
| August 1, 2022 |
EX-10.15 15 exh1015.htm EXHIBIT 10.15 EXHIBIT 10.15 PORTAGE BIOTECH INC. 2021 EQUITY INCENTIVE PLAN Restricted Share Unit Award and Dividend Equivalent Rights Agreement This Restricted Share Unit Award and Dividend Equivalent Rights Agreement (this “Agreement”), dated as of the Grant Date, is between Portage Biotech Inc., a corporation formed under the laws of the Territory of the British Virgin I |
